Literature DB >> 22799886

Chromatography purification of canine adenoviral vectors.

María Mercedes Segura1, Meritxell Puig, Mercè Monfar, Miguel Chillón.   

Abstract

Canine adenovirus vectors (CAV2) are currently being evaluated for gene therapy, oncolytic virotherapy, and as vectors for recombinant vaccines. Despite the need for increasing volumes of purified CAV2 preparations for preclinical and clinical testing, their purification still relies on the use of conventional, scale-limited CsCl ultracentrifugation techniques. A complete downstream processing strategy for CAV2 vectors based on membrane filtration and chromatography is reported here. Microfiltration and ultra/diafiltration are selected for clarification and concentration of crude viral stocks containing both intracellular and extracellular CAV2 particles. A DNase digestion step is introduced between ultrafiltration and diafiltration operations. At these early stages, concentration of vector stocks with good recovery of viral particles (above 80%) and removal of a substantial amount of protein and nucleic acid contaminants is achieved. The ability of various chromatography techniques to isolate CAV2 particles was evaluated. Hydrophobic interaction chromatography using a Fractogel propyl tentacle resin was selected as a first chromatography step, because it allows removal of the bulk of contaminating proteins with high CAV2 yields (88%). An anion-exchange chromatography step using monolithic supports is further introduced to remove the remaining contaminants with good recovery of CAV2 particles (58-69%). The main CAV2 viral structural components are visualized in purified preparations by electrophoresis analyses. Purified vector stocks contained intact icosahedral viral particles, low contamination with empty viral capsids (10%), and an acceptable total-to-infectious particle ratio (below 30). The downstream processing strategy that was developed allows preparation of large volumes of high-quality CAV2 stocks.

Entities:  

Mesh:

Year:  2012        PMID: 22799886     DOI: 10.1089/hgtb.2012.058

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  7 in total

Review 1.  Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages.

Authors:  Petra Kramberger; Lidija Urbas; Aleš Štrancar
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Production and purification of non replicative canine adenovirus type 2 derived vectors.

Authors:  Marion Szelechowski; Corinne Bergeron; Daniel Gonzalez-Dunia; Bernard Klonjkowski
Journal:  J Vis Exp       Date:  2013-12-03       Impact factor: 1.355

Review 3.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

4.  Evaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration.

Authors:  Piergiuseppe Nestola; Duarte L Martins; Cristina Peixoto; Susanne Roederstein; Tobias Schleuss; Paula M Alves; José P B Mota; Manuel J T Carrondo
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

5.  Concentration and purification of enterovirus 71 using a weak anion-exchange monolithic column.

Authors:  Ashok Raj Kattur Venkatachalam; Milene Szyporta; Tanja Kristin Kiener; Premanand Balraj; Jimmy Kwang
Journal:  Virol J       Date:  2014-05-27       Impact factor: 4.099

6.  Development of indirect ELISA for the detection of canine adenovirus type 2 antibodies in dog sera.

Authors:  Dong Kun Yang; Ha Hyun Kim; Siu Lee; Dongryul Oh; Jae Young Yoo; Bang Hun Hyun
Journal:  J Vet Sci       Date:  2020-07       Impact factor: 1.672

Review 7.  Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.

Authors:  Guy-Alain Junter; Laurent Lebrun
Journal:  J Pharm Anal       Date:  2020-01-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.